First-Pass Metabolism

Overview

First-pass metabolism (also called the first-pass effect or presystemic metabolism) refers to the phenomenon in which an orally administered compound is significantly metabolized before it reaches the systemic circulation. This processing occurs primarily in the gastrointestinal (GI) tract and liver, and it is the principal reason why the vast majority of peptides are not orally bioavailable.

Understanding first-pass metabolism is essential for interpreting why most peptides must be administered by injection, and why the development of oral peptide formulations — such as oral semaglutide (Rybelsus) — represents a major pharmaceutical achievement.

The First-Pass Pathway

When a compound is swallowed, it encounters a series of metabolic barriers before reaching the bloodstream:

1. Gastric Degradation

The stomach presents a hostile environment for peptides:

• Low pH (1.5-3.5) — Acid hydrolysis can denature peptide secondary structures and cleave acid-labile bonds
• Pepsin — The primary gastric protease, active at low pH, begins cleaving peptide bonds
• Mechanical mixing — Churning exposes peptides to the full volume of gastric acid and enzymes

2. Intestinal Degradation

The small intestine contains the highest concentration of digestive enzymes:

• Pancreatic proteases — Trypsin, chymotrypsin, elastase, and carboxypeptidases collectively degrade most peptide structures
• Brush border peptidases — Membrane-bound enzymes on intestinal epithelial cells that further cleave peptide fragments
• Alkaline pH — The intestinal pH (6-7.5) activates different proteases than the stomach

3. Intestinal Wall Metabolism

Even peptide fragments that survive luminal degradation face additional barriers during absorption:

• Cytochrome P450 enzymes — CYP3A4 in intestinal epithelial cells metabolizes many xenobiotics
• Efflux transporters — P-glycoprotein (P-gp) and other transporters actively pump absorbed molecules back into the intestinal lumen
• Poor membrane permeability — Most peptides are too large, polar, and hydrophilic to cross the lipid bilayer of intestinal epithelial cells efficiently

4. Hepatic Metabolism

Compounds absorbed from the GI tract travel via the portal vein directly to the liver before entering the general circulation. The liver contains:

• Cytochrome P450 enzymes — Extensive Phase I metabolism
• Conjugation enzymes — Phase II metabolism (glucuronidation, sulfation, acetylation)
• Hepatic proteases — Additional peptide degradation
• Biliary excretion — Some compounds are excreted into bile and returned to the intestine (enterohepatic circulation)

Impact on Peptides

For most peptides, the cumulative effect of these barriers results in oral bioavailability well below 1%. The few peptides with even modest oral bioavailability share specific characteristics:

• Small size — Di- and tripeptides can use active peptide transporters (PepT1) for absorption
• Cyclic structure — Cyclization improves protease resistance and membrane permeability (e.g., cyclosporine)
• Non-natural amino acids — D-amino acids and other modifications resist protease recognition
• Lipophilic character — Increased hydrophobicity improves membrane crossing

Strategies to Overcome First-Pass Metabolism

Alternative Routes of Administration

Bypassing the GI tract entirely eliminates first-pass metabolism:

• Subcutaneous injection — Most common route for peptide therapeutics; avoids GI and hepatic first pass
• Intravenous injection — 100% bioavailability by definition
• Intranasal — Bypasses first-pass; used for some neuropeptides that can access the brain directly via the blood-brain barrier bypass
• Transdermal — Avoids first-pass but limited by skin permeability
• Sublingual/buccal — Absorption through oral mucosa into systemic circulation, bypassing hepatic first pass

Formulation Strategies for Oral Delivery

Pharmaceutical approaches to improving oral peptide bioavailability include:

• Enteric coatings — Protect peptides from gastric acid, releasing them in the intestine
• Protease inhibitors — Co-administered compounds that temporarily suppress digestive enzyme activity
• Absorption enhancers — Compounds like SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), used in oral semaglutide, that transiently increase intestinal permeability and protect the peptide from local degradation
• Nanoparticle encapsulation — Protective carriers that shield peptides and facilitate epithelial crossing
• Mucoadhesive systems — Formulations that adhere to intestinal mucosa, increasing contact time and local concentration

Structural Modifications

• PEGylation — Can improve stability in the GI tract, though primarily used for parenteral formulations
• Lipidation — Fatty acid conjugation (as in semaglutide and liraglutide) that promotes albumin binding post-absorption
• Pro-drug approaches — Inactive precursors that are converted to the active peptide after absorption

Clinical Significance

The successful development of oral semaglutide (Rybelsus) using SNAC technology demonstrated that oral peptide delivery is achievable, though with significant constraints — oral semaglutide has approximately 1% bioavailability, requiring a 14 mg oral dose to achieve exposure comparable to a 1 mg subcutaneous injection. Patients must take it on an empty stomach with minimal water and wait 30 minutes before eating.

Ongoing development of oral non-peptide GLP-1 agonists (such as orforglipron) represents an alternative approach: designing small molecules that activate peptide receptors without the pharmacokinetic challenges inherent to peptide oral delivery.

First-pass metabolism remains the fundamental pharmacokinetic challenge for peptide therapeutics, and understanding it is essential for anyone interpreting peptide research or evaluating the feasibility of different administration routes.